Overview

* Evolent Health Q3 2025 revenue beats analyst expectations

* Company announces over $500 mln in new annualized revenue for 2026

Outlook

* Evolent expects Q4 2025 revenue between $462 mln and $472 mln

* Company anticipates 2025 full-year revenue of $1.87 bln to $1.88 bln

* Evolent forecasts prelim 2026 revenue to reach $2.5 bln

Result Drivers

* NEW CONTRACTS - Evolent signed two new revenue agreements, totaling thirteen for the year, contributing to expected 2026 revenue growth

* PRODUCT INNOVATIONS - Innovations in member navigation and Oncology Care Partners are driving growth, per CEO Seth Blackley

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $479.53 $467.50

Revenue mln mln (14

Analysts

)

Q3 Net -$26.93

Income mln

Q3 $38.96

Adjusted mln

EBITDA

Q3 8.10%

Adjusted

EBITDA

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Evolent Health Inc ( EVH ) is $15.50, about 59% above its November 5 closing price of $6.35

* The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)